37 results match your criteria: "J.A.U.; and Dartmouth Institute for Health Policy and Clinical Practice[Affiliation]"
Leukoencephalopathy due to variants in associated congenital myasthenic syndrome.
Neurology
February 2019
From the Murdoch Children's Research Institute (G.H., C.S.), Parkville, Melbourne; Institute for Molecular Bioscience (G.H., J.C., C.S.), the University of Queensland, Brisbane, Australia; Neurology Division (S.S., B.P., P.J.), Department of Pediatrics, Lady Hardinge Medical College, New Delhi, India; Division of Neurology (P.J.), Department of Pediatrics, the Hospital for Sick Children, Toronto, Canada; Data61 (S.J.B.), Commonwealth Scientific and Industrial Research Organisation, Brisbane, Australia; Hôpital Marin (J.A.U.), Centre Neuromusculaire, Filnemus, Hendaye, France; Department of Pathology (R.K.S.), G.B. Pant Hospital, New Delhi, India; Illumina, Inc. (R.J.T.), San Diego, CA; Department of Child Neurology (M.S.v.d.K.), Emma Children's Hospital, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam and Amsterdam Neuroscience; and Department of Functional Genomics (M.S.v.d.K.), Neuroscience Campus Amsterdam, the Netherlands.
Objective: To determine the molecular etiology of disease in 4 individuals from 2 unrelated families who presented with proximal muscle weakness and features suggestive of mitochondrial disease.
Methods: Clinical information and neuroimaging were reviewed. Genome sequencing was performed on affected individuals and biological parents.
Neighborhood Socioeconomic Disadvantage and Care After Myocardial Infarction in the National Cardiovascular Data Registry.
Circ Cardiovasc Qual Outcomes
June 2018
Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital Heart & Vascular Center and Harvard Medical School, Boston, MA (D.L.B.).
Background: Patients living in disadvantaged neighborhoods are at high risk for adverse outcomes after acute myocardial infarction (MI). Whether residential socioeconomic status (SES) is associated with quality of in-hospital care among patients presenting with MI is unclear.
Methods And Results: Multivariable logistic regression was used to examine the relationship between SES, quality of care, and in-hospital cardiovascular outcomes among patients with MI from diverse SES neighborhoods from July 2008 to December 2013, at 586 participating hospitals in the Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With The Guidelines quality improvement program.
Response by Lytvyn et al to Letter Regarding Article, "Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials".
Circulation
May 2018
Department of Medicine, Division of Nephrology, University Health Network (Y.L., J.A.L., D.Z.I.C.).
Cardiovascular Outcomes and Risks After Initiation of a Sodium Glucose Cotransporter 2 Inhibitor: Results From the EASEL Population-Based Cohort Study (Evidence for Cardiovascular Outcomes With Sodium Glucose Cotransporter 2 Inhibitors in the Real World).
Circulation
April 2018
Janssen Research & Development, LLC, Titusville/Raritan, NJ (Z.Y., N.R.).
Background: Clinical trials have shown cardiovascular benefits and potential risks from sodium glucose cotransporter 2 inhibitors (SGLT2i). Trials may have limited ability to address individual end points or safety concerns.
Methods: We performed a population-based cohort study among patients with type 2 diabetes mellitus with established cardiovascular disease newly initiated on antihyperglycemic agents within the US Department of Defense Military Health System between April 1, 2013, and December 31, 2016.
Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials.
Circulation
October 2017
From Department of Medicine, Division of Nephrology, University Health Network, University of Toronto, Ontario, Canada (Y.L., J.A.L., D.Z.I.C.); Department of Pediatrics, Division of Endocrinology, University of Colorado School of Medicine, Aurora (P.B.); Women's College Research Institute and Department of Medicine, Division of Cardiology, Women's College Hospital, University of Toronto, Ontario, Canada (J.A.U.); Peter Munk Cardiac Centre, University Health Network, University of Toronto, Ontario, Canada (J.A.U.); and Department of Medicine, Division of Endocrinology and Metabolism, University Health Network and Sunnybrook Health Sciences Centre, University of Toronto, Ontario, Canada (J.A.L.).
Despite current established therapy, heart failure (HF) remains a leading cause of hospitalization and mortality worldwide. Novel therapeutic targets are therefore needed to improve the prognosis of patients with HF. The EMPA-REG OUTCOME trial ([Empagliflozin] Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) demonstrated significant reductions in mortality and HF hospitalization risk in patients with type 2 diabetes mellitus (T2D) and cardiovascular disease with the antihyperglycemic agent, empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor.
View Article and Find Full Text PDFUse of Sodium Glucose Cotransporter 2 Inhibitors in the Hands of Cardiologists: With Great Power Comes Great Responsibility.
Circulation
December 2016
From Division of Nephrology, Department of Medicine (D.Z.I.C.) and Peter Munk Cardiac Centre (J.A.U.), Toronto General Hospital, Toronto, ON, Canada; Department of Physiology, Banting and Best Diabetes Centre (D.Z.I.C.) and Heart and Stroke Richard Lewar Centre of Excellence in Cardiovascular Research, Department of Medicine (D.Z.I.C., J.A.U.), University of Toronto, Toronto, ON, Canada; and Women's College Research Institute and Cardiovascular Division, Department of Medicine, Women's College Hospital, Toronto, ON, Canada (J.A.U.).
Individualizing Duration of Dual Antiplatelet Therapy After Acute Coronary Syndrome or Percutaneous Coronary Intervention.
Circulation
May 2016
From Terrence Donnelly Heart Center, St. Michael's Hospital, University of Toronto, ON, Canada (A.B., A.N.C.); Brigham and Women's Hospital Heart & Vascular Center, Harvard Medical School, Boston, MA (D.L.B.,); Population Health Research Institute, McMaster University and Hamilton Health Sciences, ON, Canada (J.W.E., S.R.M.); Vancouver Hospital, University of British Columbia, Vancouver, Canada (G.B.J.M.); Division of Cardiology, Department of Medicine, Schulich Heart Centre, Sunnybrook Health Sciences Centre, University of Toronto, ON, Canada (E.A.C.); Division of Cardiology, Rouge Valley Health System, Scarborough, ON, Canada (R.V.); Peter Munk Cardiac Centre, Toronto General Hospital and Women's College Hospital, University of Toronto, ON, Canada (J.A.U.); University of Ottawa, ON, Canada (J.N.); Montreal Heart Institute, Université de Montréal, QC, Canada (J.-F.T.); and Division of Cardiac Surgery, Keenen Research Centre for Biomedical Science and Li Ka Shing Knowledge Institute of St. Michael's Hospital, Toronto, ON, Canada (S.V.).
A Multicenter Observational Study of Incretin-based Drugs and Heart Failure.
N Engl J Med
March 2016
From the Center for Clinical Epidemiology, Lady Davis Research Institute, Jewish General Hospital (K.B.F., L.A., P.E.), the Departments of Medicine (K.B.F., P.E.), Oncology (L.A.), Pediatrics (R.W.P.), and Epidemiology, Biostatistics, and Occupational Health (R.W.P.), McGill University, and the Research Institute of the McGill University Health Centre (R.W.P.), Montreal, the Manitoba Centre for Health Policy, Department of Community Health Sciences (M.D., L.T.), and the Section of Gastroenterology, Division of Internal Medicine (L.T.), University of Manitoba, Winnipeg, the Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, Vancouver (C.R.D.), the Department of Medicine, Western University, London, ON (K.K.C.), the Health Quality Council, Saskatoon, SK (N.H.), the Institute for Clinical Evaluative Sciences (J.M.P., J.A.U.), Institute of Health Policy, Management and Evaluation, University of Toronto (J.M.P.), and the Cardiovascular Division, Women's College Hospital, Peter Munk Cardiac Centre of the University Health Network, and the University of Toronto (J.A.U.), Toronto, the Department of Family Medicine, McMaster University, Hamilton, ON (J.M.P.), and the Department of Family Medicine, University of Calgary, Calgary, AB (T.C.T.) - all in Canada.
Background: There is concern that antidiabetic incretin-based drugs, including dipeptidyl peptidase 4 (DPP-4) inhibitors and glucagon-like peptide 1 (GLP-1) analogues, can increase the risk of heart failure. Ongoing clinical trials may not have large enough samples to effectively address this issue.
Methods: We applied a common protocol in the analysis of multiple cohorts of patients with diabetes.
Effect of Intensive Versus Standard Blood Glucose Control in Patients With Type 2 Diabetes Mellitus in Different Regions of the World: Systematic Review and Meta-analysis of Randomized Controlled Trials.
J Am Heart Assoc
May 2015
Peter Munk Centre of Excellence in Multinational Clinical Trials, University Health Network, Heart & Stroke Richard Lewar Centre of Excellence, University of Toronto, Ontario, Canada (J.A.U., M.E.F.).
Background: Regional variation in type 2 diabetes mellitus care may affect outcomes in patients treated with intensive versus standard blood glucose control. We sought to evaluate these differences between North America and the rest of the world.
Methods And Results: Databases were searched from their inception through December 2013.
The Cardiovascular Health in Ambulatory Care Research Team (CANHEART): using big data to measure and improve cardiovascular health and healthcare services.
Circ Cardiovasc Qual Outcomes
March 2015
From the Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada (J.V.T., A.C., L.R.D., D.T.K., G.L.B., K.T., L.C.M., H.G., P.C.A., W.H., M.K.K., H.C.W., C.L.A., A.S.G., D.A.A., D.S.L., C.A.J., R.S.B., J.A.U., M.R.R., T.A.S.); Division of Cardiology, Schulich Heart Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada (J.V.T., D.T.K., H.C.W.); University of Toronto, Toronto, Ontario, Canada (J.V.T., A.C., D.T.K., G.L.B., K.T., P.C.A., M.K.K., H.C.W., C.L.A., A.S.G., D.A.A., D.S.L., C.A.J., R.S.B., J.A.U., T.A.S.); Division of Endocrinology, Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Ontario, Canada (G.L.B.); Toronto Western Hospital Family Health Team, University Health Network, Toronto, Ontario, Canada (K.T.); Ottawa Research Group for Primary Health Care, Ottawa, Ontario, Canada (W.H.); Department of Family Medicine, University of Ottawa, Ottawa, Ontario, Canada (W.H.); Division of General Internal Medicine and Clinical Epidemiology, University Health Network, Toronto, Ontario, Canada (M.K.K.); Division of Emergency Medicine (C.L.A.) and Division of Respirology (A.S.G.), Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; Toronto Rehabilitation Institute, University Health Network, Toronto, Ontario, Canada (D.A.A.); Division of Cardiology, Peter Munk Cardiac Centre and Joint Department of Medical Imaging, University Health Network, Toronto, Ontario, Canada (D.S.L.); College of Pharmacy, Western University of Health Sciences, Pomona, CA (C.A.J.); Women's College Hospital Institute for Health Systems Solutions and Virtual Care, Toronto, Ontario, Canada (R.S.B.); Cardiovascular Division, Women's College Hospital, Toronto, Ontario, Canada (R.S.B., J.A.U.); and Dartmouth Institute for Health Policy and Clinical Practice, Lebanon, NH (T.A.S.).
Background: The CArdiovascular HEalth in Ambulatory care Research Team (CANHEART) is conducting a unique, population-based observational research initiative aimed at measuring and improving cardiovascular health and the quality of ambulatory cardiovascular care provided in Ontario, Canada. A particular focus will be on identifying opportunities to improve the primary and secondary prevention of cardiovascular events in Ontario's diverse multiethnic population.
Methods And Results: A population-based cohort comprising 9.
Cardiovascular and pulmonary adverse events in patients treated with BCR-ABL inhibitors: Data from the FDA Adverse Event Reporting System.
Am J Hematol
April 2015
Department of Leukemia, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas.
Rare but serious cardiovascular and pulmonary adverse events (AEs) have been reported in patients with chronic myeloid leukemia treated with BCR-ABL inhibitors. Clinical trial data may not reflect the full AE profile of BCR-ABL inhibitors because of stringent study entry criteria, relatively small sample size, and limited duration of follow-up. To determine the utility of the FDA AE Reporting System (FAERS) surveillance database for identifying AEs possibly associated with the BCR-ABL inhibitors imatinib, dasatinib, and nilotinib in the postmarketing patient population, we conducted Multi-Item Gamma Poisson Shrinker disproportionality analyses of FAERS reports on AEs in relevant system organ classes.
View Article and Find Full Text PDFHeart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial.
Circulation
October 2014
From the Thrombolysis in Myocardial Infarction (TIMI) Study Group, Cardiovascular Division (B.M.S., E.B., M.A.C., D.A.M., K.I., A.A.U.-E., D.L.B.) and Department of Pathology (P.J.), Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Diabetes Unit (I.R., O.M.), Division of Internal Medicine, Hadassah Hebrew University Hospital, Jerusalem, Israel; Cardiovascular Division (J.A.U.), Women's College Hospital and Toronto General Hospital, University of Toronto, Toronto, Canada; AstraZeneca Research and Development (P.S.P., B.H.), Gaithersburg, MD; Bristol-Myers Squibb (R.F.), Princeton, NJ; Cardiovascular Research Institute (B.S.L.), Lady Davis Carmel Medical Center and Ruth and Bruce Rappaport School of Medicine, Technion-Israel Institute of Technology, Haifa, Israel; Cardiovascular Medicine (D.K.M.) and Division of Endocrinology, Department of Internal Medicine (J.D.), University of Texas Southwestern Medical Center, Dallas, TX; University Hospital Department (G.S.), Département Hospitalo-Universitaire FIRE (Fibrosis, Inflammation, Remodelling), Institut National de la Santé et de la Recherche Médicale (INSERM) Unit 1148, Université Paris-Diderot, and Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, Paris, France (P.G.S.), Imperial College, Institute of Cardiovascular Medicine and Science, Royal Brompton Hospital, London, UK.
Background: Diabetes mellitus and heart failure frequently coexist. However, few diabetes mellitus trials have prospectively evaluated and adjudicated heart failure as an end point.
Methods And Results: A total of 16 492 patients with type 2 diabetes mellitus and a history of, or at risk of, cardiovascular events were randomized to saxagliptin or placebo (mean follow-up, 2.